Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.78 USD | -0.19% | -0.09% | -1.55% |
13/03 | Top Premarket Decliners | MT |
12/03 | JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating | MT |
Business Summary
Number of employees: 157
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cancer Immunotherapies
100.0
%
| 268 | 100.0 % | 13 | 100.0 % | -95.29% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Belgium
100.0
%
| 268 | 100.0 % | 13 | 100.0 % | -95.29% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michel Detheux
FOU | Founder | 57 | 01/12/01 |
Matthew Gall
DFI | Director of Finance/CFO | 47 | 01/20/01 |
Yvonne McGrath
CTO | Chief Tech/Sci/R&D Officer | 50 | 01/20/01 |
Matthew Call
COO | Chief Operating Officer | 51 | 01/19/01 |
Adi Osovsky
LAW | General Counsel | - | 01/21/01 |
Human Resources Officer | - | 01/20/01 | |
Bronson Crouch
PRN | Corporate Officer/Principal | 51 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ann Rhoads
BRD | Director/Board Member | 58 | 01/20/01 |
David Hallal
CHM | Chairman | 57 | 01/18/01 |
Director/Board Member | 52 | 01/18/01 | |
Jill DeSimone
BRD | Director/Board Member | 68 | 07/03 |
Michel Detheux
FOU | Founder | 57 | 01/12/01 |
Robert Iannone
BRD | Director/Board Member | 57 | 03/21/03 |
Tony Ho
BRD | Director/Board Member | 58 | 03/21/03 |
Aaron Davis
BRD | Director/Board Member | 45 | 01/20/01 |
David Lee
BRD | Director/Board Member | - | 05/12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 35,965,522 | 35,771,361 ( 99.46 %) | 0 | 99.46 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.55% | 388M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.46% | 22.18B | |
-16.67% | 21.2B | |
-8.58% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- ITOS Stock
- Company iTeos Therapeutics, Inc.